课题基金 / 基金详情

项目摘要

项目成果

Madhav Thambisetty的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The DREAM study began on 9/16/2019. 20 drugs have been tested for their ability to lower the risk of Alzheimer's disease and related dementias (ADRD). These drugs are commonly used to treat conditions including rheumatoid arthritis, asthma, diabetes, hypertension and epilepsy. Encouraging results from several of the drugs tested are being confirmed through parallel validation experiments in cell culture-based assays and long-term in vivo studies in transgenic AD mouse models. These studies also include evaluation of candidate AD drugs for their ability to rescue impaired hippocampal synaptic plasticity in APP/PS1 mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
New Cures from Old Medicines - Targeting abnormal metabolism in AD
  • 批准号:
    10019244
  • 项目类别:
  • 资助金额:
    $10.82万
  • 财政年份:
    --
  • 负责人:
    Madhav Thambisetty
  • 依托单位:
Understanding mechanisms and seeking novel biomarkers in Alzheimer's disease
  • 批准号:
    10688757
  • 项目类别:
  • 资助金额:
    $18.99万
  • 财政年份:
    --
  • 负责人:
    Madhav Thambisetty
  • 依托单位:
New Cures from Old Medicines - Targeting abnormal metabolism in Alzheimer's Disease
  • 批准号:
    10688800
  • 项目类别:
  • 资助金额:
    $14.52万
  • 财政年份:
    --
  • 负责人:
    Madhav Thambisetty
  • 依托单位:
Understanding mechanisms and seeking novel biomarkers in Alzheimer's disease
  • 批准号:
    10250845
  • 项目类别:
  • 资助金额:
    $296.2万
  • 财政年份:
    --
  • 负责人:
    Madhav Thambisetty
  • 依托单位:
海外基金